Janux Therapeutics, Inc. (JANX) Balance Sheet

The balance sheet is weakening as retained earnings deficit deepens by roughly $22M per quarter, consistent with the R&D burn. However, total assets have stabilized around $1.0B, suggesting that recent capital raises have offset operational losses, but the trend is unsustainable without additional funding or milestone inflows.

The low debt levels suggest no immediate refinancing risk, but the company's capital structure is equity-heavy, which may lead to dilution if additional capital is raised. The $21M debt is likely modest and manageable, but the real risk is the need for future equity issuance to fund operations, given the negative retained earnings.

The negligible PPE and absence of goodwill suggest that JANX's value lies in its intellectual property and clinical pipeline, not physical assets. This is typical for biotech, but it also means that asset impairments are unlikely, and the balance sheet provides little collateral for debt financing.

The equity base is being eroded by operating losses, but the company has not returned capital to shareholders, consistent with a reinvestment strategy. The lack of buybacks and dividends is typical for a pre-commercial biotech, but the growing deficit highlights the need for future profitability or capital raises to sustain operations.

The current ratio is strong, but the absolute cash position is concerning, especially given the quarterly burn of around $30M. The $27.8M cash provides less than one quarter of runway, suggesting that JANX will need to raise capital soon or secure additional collaboration payments to avoid liquidity strain.